ClinicalTrials.gg
RecruitingNCT07040982Updated Nov 3, 2026

Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

A Phase 1 interventional study of Asciminib and Biospecimen Collection in B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 3, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center — 10 open to participants now, 28 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · City of Hope Medical Center.

Planned enrollment
28th of 50
30 · median 32
Started
2025
with 4 others
Phase 1
22 of 55
6 open now
Primary completion
2029-06
later than 25 of 27 live
Registered
54th of 55
by date

Among the 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center, this one is the 28th largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2025, is one of 22 in phase 1, reaches primary completion later than 25 of the 27 other live ones, and was the 54th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

10 of the 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase I trial tests the safety, side effects and best dose of asciminib as maintenance treatment for adults with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) who have undergone cellular therapies such as hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR) T cell therapy. Maintenance treatment is given to help keep cancer from coming back after it has disappeared following initial therapy. Asciminib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving asciminib may be safe and tolerable as maintenance treatment for adult patients with Philadelphia chromosome positive ALL who have undergone cellular therapies.

Read the detailed description

PRIMARY OBJECTIVES:

I. Evaluate the safety of asciminib maintenance in adults with Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) in morphological complete remission (CR) post hematopoietic stem cell transplantation (HSCT; Arm 1) or chimeric antigen receptor (CAR) T cell therapy (Arm 2).

II. Determine the recommended phase 2 dosing (RP2D) of asciminib maintenance post cellular therapies in Ph+ ALL in each arm.

SECONDARY OBJECTIVES:

I. Evaluate feasibility of asciminib maintenance measured as the number of patients who continue asciminib > 3 cycles post cellular therapy.

II. Duration of response. III. Timing for minimal residual disease (MRD) and full relapse. IV. Relapse free survival at 1 year post cellular therapy. V. Overall survival at 1 year post cellular therapy. VI. Non-relapse mortality at 1 year post cellular therapy. VII. Relapse at 1 year post cellular therapy. VIII. Rates of asciminib discontinuation and interruption due to toxicity at 1 year post cellular therapy.

IX. Rate of switching to another tyrosine kinase inhibitor (TKI) at 1 year post cellular therapy X. Rate and grade of acute graft-versus-host disease (GVHD) at 180 days post initiation of asciminib maintenance post HSCT. (Arm 1) XI. Rate and grade of chronic GVHD at 1 year post initiation of asciminib maintenance post HSCT. (Arm 1) XII. GVHD-free, relapse-free survival (GRFS) at 1 year post HSCT. (Arm 1)

EXPLORATORY OBJECTIVES:

I. For patients who are MRD-negative, evaluate MRD relapse by clonoSEQ during therapy.

II. Evaluate immune cell populations and immune reconstitution post-transplant during asciminib therapy.

III. Evaluate the impact of prevalent BCR-ABL mutations and treatment emergent BCR-ABL mutations.

IV. Evaluate B-cell aplasia and CAR T cell persistence during asciminib therapy. (Arm 2) V. Quality of life assessments using Patient Reported Outcomes Measurement Information System (PROMIS).

OUTLINE: This is a dose-escalation study of asciminib followed by a dose-expansion study.

Patients receive asciminib orally (PO) once daily (QD) or twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography during screening and as clinically indicated, and bone marrow biopsy, bone marrow aspirate and blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 30 days then every 3 months for 1 year.

03

Conditions studied

  • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PRE-SCREENING: Documented of the participant and/or legally authorized representative
  • PRE-SCREENING: Age ≥ 18 years
  • PRE-SCREENING: Participant was diagnosed with Ph+ ALL according to World Health Organization criteria. The BCR::ABL1 translocation may be detected by fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next generation sequencing (NGS), or cytogenetics at least once any time prior to cellular therapy. Participants may have p190 or p220 isoform, and participants with T315I mutation are not excluded
  • PRE-SCREENING: Participant meets one of the following criteria:

    • Arm 1: Have a date for scheduled within the next 30 days or have received HSCT within the last 30 days. Note: all HSCT donors, conditioning regimens, and prophylaxis regimens will be acceptable.
    • Arm 2: Have a date for CAR T cell infusion scheduled within the next 30 days or have received CAR T cell infusion within the last 30 days
  • PRE-SCREENING: History of pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
  • PRE-SCREENING: History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Documented informed consent of the participant and/or legally authorized representative.

    • Assent, when appropriate, will be obtained per institutional guidelines
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: (ECOG) ≤ 2
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Participant is between day +30 and +150 after one of the following cellular therapies:

    • Arm 1: HSCT

      • Participants on Arm 1 must be fully engrafted post-HSCT.
    • Arm 2: CD19-targeted CAR T cell therapy (brexucabtagene autoleucel, tisagenlecleucel, obecabtagene autoleucel, CD19 CAR T cell therapy)

      • Participants on Arm 2 must be fully recovered from cytopenia
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Day 30 (+/- 5 days) marrow post cellular therapy should show evidence of complete morphologic remission defined as \< 5% bone marrow (BM) blasts, no extramedullary disease, and transfusion independence
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Participant should have no morphological evidence of relapse
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: (ANC) ≥ 500/mm\^3 for 3 days

    • NOTE: Patients are allowed growth factors
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: ≥ 75,000/mm\^3
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: ≥ 9g/dL
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Total ≤ 1.5 X (ULN) (unless has Gilbert's disease)
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: (AST) ≤ 3.0 x ULN
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Alanine aminotransferase (ALT) ≤ 3.0 x ULN
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: serum creatinine \<1.5 mg/dL
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: (LVEF) ≥ 50%

    • Note: To be performed within 28 days prior to day 1 of protocol therapy
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Bazett's interval (QTcB) ≤ 480 ms

    • Note: To be performed within 28 days prior to day 1 of protocol therapy
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Oxygen (O2) saturation > 90% on room air
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Seronegative for antigen (Ag)/antibody (Ab) combination (combo), virus (HCV), active virus (HBV) (surface antigen negative) OR

    • If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Meets other institutional and federal requirements for infectious disease titer requirements

    • Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Women of (WOCBP): Negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Agreement by females and males of childbearing potential* to use an effective method of or abstain from heterosexual activity for the course of the study through at least 120 days after the last dose of protocol therapy.

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment failure with asciminib
  • Treatment with strong inducers of is not allowed and should be switched to an alternative at least 1 week prior to the start of study treatment
  • ARM 1: Treatment with prior is allowed
  • ARM 2: Treatment with prior CAR T cell therapy is allowed
  • Cardiac or cardiac repolarization abnormality, including any of the following:

    • History within 6 months prior to starting study treatment of myocardial infarction (MI), or coronary artery bypass graft (CABG)
    • cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third-degree AV block)
    • Fridericia's interval (QTcF) at screening ≥ 450 msec (male patients), ≥ 470 msec (female patients)
    • Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome
  • History of pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
  • ARM 1: Active grade 3 or higher (GVHD) after allogeneic HSCT within 14 days of enrollment. Note: prednisone administration (flat dose of 0.5 mg/kg) is allowed. Patients receiving any other medication to control active/progressive GVHD will be excluded
  • Clinically significant uncontrolled illness
  • Active infection not responding to treatment
  • Other active . Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • Females only: Pregnant or breastfeeding
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Treatment (Asciminib)

    Patients receive asciminib PO QD or BID on days 1-28 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography during screening and as clinically indicated, and bone marrow biopsy, bone marrow aspirate and blood sample collection throughout the study.

    Drug: Asciminib · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Procedure: Echocardiography Test · Other: Survey Administration

Interventions

  • Given PO

    Also known as: ABL 001, ABL-001, ABL001

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • ProcedureEchocardiography Test

    Undergo echocardiography

    Also known as: EC, Echocardiography

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The toxicity/adverse event information recorded on each subject will include type, severity, duration, attribution/ association with the study agent by arm and cycle. Tables will be constructed to summarize the observed incidence, severity and type of toxicity, including infection. Point estimates and 90% confidence intervals will be provided.

    Time frame: From start of treatment on day 1 to the end of cycle 1 on day 28

Secondary outcomes

  1. Number of patients who have completed at least 3 cycles of asciminib and have taken ≥ 70% planned doses in each cycle post cellular therapy

    The protocol therapy will be deemed feasible if \> 70% or higher of patients meet this feasibility criteria. Point estimates and 90% confidence intervals will be provided.

    Time frame: Up to completion of 3 cycles (cycle length= 28 days)

  2. Duration of remission

    Point estimates and 90% confidence intervals will be provided.

    Time frame: Up to 1 year after completion of study treatment

  3. Relapse including minimal residual disease (MRD) relapsed

    MRD relapse assed by polymerase chain reaction (PCR) and flow cytometry. MRD relapse is defined as detectable leukemic cells at \> 0.01% in morphological remission bone marrow. However, due to rate of false positivity of PCR BCR::ABL1, confirmation is required by either positive MRD flow or/and clonoSEQ \> 0.01%. Will be calculated using the competing risk method. Point estimates and 90% confidence intervals will be provided.

    Time frame: Up to 1 year after completion of study treatment

  4. Relapse free survival

    Kaplan-Meier curves will be used for survival endpoints. Point estimates and 90% confidence intervals will be provided.

    Time frame: From start of protocol therapy to relapse, or death, up to 1 year after completion of study treatment

  5. Overall survival

    Kaplan-Meier curves will be used for survival endpoints. Point estimates and 90% confidence intervals will be provided.

    Time frame: From start of protocol therapy to death regardless of cause, up to 1 year after completion of study treatment

  6. Non-relapse mortality

    Will be calculated using the competing risk method. Point estimates and 90% confidence intervals will be provided.

    Time frame: From start of protocol therapy to death without relapse/progression, up to 1 year after completion of study treatment

  7. Switching tyrosine kinase inhibitors (TKI)

    Defined as changing treatment to a different TKI due to asciminib toxicity or intolerability per the treating physician judgment. Point estimates and 90% confidence intervals will be provided.

    Time frame: Up to 1 year after completion of study treatment

  8. Asciminib discontinuation

    Discontinuation is defined as not taking asciminib \> 28 days due to treatment-related toxicity. Point estimates and 90% confidence intervals will be provided.

    Time frame: Up to 1 year

  9. Asciminib interruption

    Interruption is defined as not taking asciminib for \> 7 days because of treatment-related toxicity. Point estimates and 90% confidence intervals will be provided.

    Time frame: Up to 1 year

  10. Rate of acute graft versus host disease (aGVHD) of grades 2-4 (arm 1)

    Documented/biopsy proven aGVHD is graded according to Mount Sinai Acute graft versus host disease (GVHD) International Consortium (MAGIC) grading. Point estimates and 90% confidence intervals will be provided.

    Time frame: From hematopoietic stem cell transplantation (HSCT) to day 180 post HSCT

  11. Rate of aGVHD of grades 3-4 (Arm 1)

    Documented/biopsy proven aGVHD is graded according to MAGIC Grading. Point estimates and 90% confidence intervals will be provided.

    Time frame: From HSCT to day 180 post HSCT

  12. GVHD-free, relapse-free survival (Arm 1)

    Kaplan-Meier curves will be used for survival endpoints. Point estimates and 90% confidence intervals will be provided.

    Time frame: From start of protocol therapy to the first observation of developing grade 3-4 aGVHD, chronic (c) GVHD requiring systemic therapy, relapse/progression, or death, whichever comes first, up to 1 year after completion of study treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2029, 41 months after the start.

Of 158 non-industry phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's planned 41 months is below that.

Counting every sponsor, half of 208 studies reached it within 55 months; a quarter within 34 and three quarters within 90.

Start moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2025, last on Nov 3, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2028 → Jun 2029, on Oct 19, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2028 → Jun 2029, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 27, 2025
StartActual
Dec 17, 2025was Dec 2026
Primary completionEst.
Jun 9, 2029was Jun 2028
CompletionEst.
Jun 9, 2029was Jun 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 19, 2026→Dec 17, 2025 (actual)
moved 2 times, Oct 19, 2026 – Nov 3, 2026
Primary completion
Jun 13, 2028→Jun 9, 2029
Oct 19, 2026
Study completion
Jun 13, 2028→Jun 9, 2029
Oct 19, 2026
Show all 2 updates
  1. Nov 3, 2026
    Start date Dec 17, 2026→Dec 17, 2025 (now actual)
  2. Oct 19, 2026
    Start date Dec 19, 2026→Dec 17, 2026
    Primary completion Jun 13, 2028→Jun 9, 2029
    Study completion Jun 13, 2028→Jun 9, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07040982
Responsible party
Sponsor
First posted
Jun 27, 2025
Start date
Dec 17, 2025
Primary completion
Jun 9, 2029 (estimated)
Completion
Jun 9, 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Ibrahim Aldoss
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion